ArticleThe Journal of international medical research2021
Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies.
Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Therapeutic Role of Probiotics for the Treatment of Dyspepsia: A Review of the Literature.Neurogastroenterology and motility · 2025Review
- Article
- Dietary microbes and functional dyspepsia: modulating the gut microecology for therapeutic benefit.Frontiers in nutrition · 2025Review
- Clinical efficacy of probiotics in improving intestinal mucosal permeability for functional dyspepsia patients with anxiety.Frontiers in microbiology · 2025Article
- Research Progress for Probiotics Regulating Intestinal Flora to Improve Functional Dyspepsia: A Review.Foods (Basel, Switzerland) · 2024Review
- Relative Frequency of Gastrointestinal Functional Disorders in Patients with Inflammatory Bowel Disease Based on Rome IV: A Case-Control Study.Advanced biomedical research · 2024Article
- Gut Microbiome-Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders.ACS chemical neuroscience · 2023Review
- Food, Dietary Patterns, or Is Eating Behavior to Blame? Analyzing the Nutritional Aspects of Functional Dyspepsia.Nutrients · 2023Review
- Probiotics in Functional Dyspepsia.Microorganisms · 2023Review
- Functional Gastrointestinal Disorders with Psychiatric Symptoms: Involvement of the Microbiome-Gut-Brain Axis in the Pathophysiology and Case Management.Microorganisms · 2022Review
- Effect of Kvass on Improving Functional Dyspepsia in Rats.Computational and mathematical methods in medicine · 2022Article
- Eosinophils, Hypoxia-Inducible Factors, and Barrier Dysfunction in Functional Dyspepsia.Frontiers in allergy · 2022Review
- The Role of Gastrointestinal Microbiota in Functional Dyspepsia: A Review.Frontiers in physiology · 2022Review
- A Journey on the Skin Microbiome: Pitfalls and Opportunities.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePostprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) are the two main forms of functional dyspepsia (FD). Probiotics are a promising therapy for FD, but current data remains heterogeneous. This work aims to evaluate a probiotic combination of
methodsPatients with FD were enrolled and divided into two groups: PDS and EPS. Probiotic alone or combined with prokinetics, antacids, or proton-pump-inhibitors were administered for 30 days. A progressive-score scale was used to evaluate symptoms in all patients at the beginning of the trial and at 15 days after the end of treatment.
resultsA cohort of 2676 patients were enrolled (1 357 with PDS; 1 319 with EPS). All patients showed significant improvements in dyspeptic symptoms following treatment. In patients with PDS, probiotic alone resulted in the lowest prevalence of symptoms following treatment, while patients with EPS showed no clear between-treatment differences.
conclusionsDyspeptic symptoms were reduced following treatment in all patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.